Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th June 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting under SEBI LODR Regulations 33, 42 & 43
Audit Opinion:
Unmodified conclusion (clean opinion) from auditors M/s B S R & Co. LLP on both standalone and consolidated financial results.
Key Financial Highlights [₹ in Crore]:
Consolidated Results:
Revenue from Operations: ₹1,625.96 (Q1 FY27) vs ₹1,302.65 (Q1 FY26) - Up 25% YoY
Total Income: ₹1,696.86 (Q1 FY27)
Adjusted EBITDA (excluding forex loss): ₹454 (28% margin) vs ₹377 (Q1 FY26) - Up 21% YoY
Profit After Tax: ₹334 (21% margin) vs ₹255 (Q1 FY26) - Up 31% YoY
EPS (Basic): ₹26.75 (Face value of ₹2 each)
Other Comprehensive Income (loss): ₹(4.26)
Total Comprehensive Income: ₹329.96
Standalone Results:
Revenue from Operations: ₹1,488.67 (Q1 FY27) vs ₹1,208.56 (Q1 FY26)
Total Income: ₹1,559.49 (Q1 FY27)
Profit After Tax: ₹315.47 (Q1 FY27) vs ₹254.97 (Q1 FY26)
EPS (Basic): ₹25.25 (Face value of ₹2 each)
Other Comprehensive Income (loss): ₹(3.32)
Total Comprehensive Income: ₹312.15
Segment-wise Performance:
Q1 FY27 Revenue Breakdown:
- Branded Generics India: ₹509 cr (24% growth YoY)
- Branded Generics Asia: ₹255 cr (16% decline YoY)
- Branded Generics Africa: ₹295 cr (30% growth YoY)
- US Generics: ₹487 cr (57% growth YoY)
- Africa Institution: ₹70 cr (83% growth YoY)
India Therapy Performance (IQVIA MAT June 2026 vs IPM):
- Cardiology: 9% vs IPM 15%
- Ophthalmology: 15% vs IPM 10%
- Dermatology: 14% vs IPM 8%
- Pain Management: 15% vs IPM 10%
- Overall: 15% vs IPM 11%
Corporate Actions:
- 1st interim dividend for FY27: ₹32 per share (face value ₹2)
- Total dividend payout: ₹399.79 crore
- Record date: Wednesday, 5th August 2026
- Payment date: On or after 18th August 2026
Other Significant Information:
- R&D expense: ₹66 cr (4% of revenue) in Q1 FY27 vs ₹56 cr in Q1 FY26
- ANDA status: 3 approvals received, 2 launched in Q1 FY27; 17 ANDAs awaiting US FDA approval
- ROCE: 37%; RONW: 28%
- Company operates in one reportable business segment: "Pharmaceuticals"
- Consolidated entities include 5 wholly-owned subsidiaries